



**Contact:**

**intellim Corporation**

Masakuni Ukita  
President & CEO  
intellim Corporation  
18F, Mainichi Intecio, 3-4-5 Umeda, Kita-ku,  
Osaka-shi, Osaka 530-0001  
Japan

+ 81-6-6343-8040  
[global@intellim.co.jp](mailto:global@intellim.co.jp)  
[www.intellim.co.jp](http://www.intellim.co.jp)

**QPS**

Ben Chien, PhD  
Chairman, President & CEO  
QPS Holdings, LLC  
Three Innovation Way, Suite 240  
Newark, DE 19711  
USA

+ 1 302-369-5110 DE office  
+ 1 650-599-9445 CA office  
[ben.chien@qps.com](mailto:ben.chien@qps.com)  
[www.qps.com](http://www.qps.com)

**iQ Pharma Services Corporation**

Masashi Iwasaki, PhD  
President  
iQ Pharma Services Corporation  
18F, Mainichi Intecio, 3-4-5 Umeda, Kita-ku,  
Osaka-shi, Osaka 530-0001  
Japan  
[info@iQ-PS.com](mailto:info@iQ-PS.com)  
[www.iQ-PS.com](http://www.iQ-PS.com)

**FOR IMMEDIATE RELEASE**

## **EXPANDING THEIR GLOBAL CLINICAL SERVICES, QPS AND INTELLIM TO FORM IQ PHARMA SERVICES - A JOINT VENTURE CONTRACT RESEARCH ORGANIZATION IN JAPAN**

(November 15, 2012; Osaka, Japan) – QPS Holdings, LLC announced today that it has concluded an agreement with intellim Corporation to form a joint venture Contract Research Organization (CRO), named iQ Pharma Services Corporation, in Japan.

As trusted drug development partners for biopharmaceutical companies, both QPS and intellim provide total drug development solutions to their clients, from basic R&D to the various stages of clinical trial conduct.

Under the terms of the agreement, iQ Pharma Services will be organized to offer Phase II through Phase IV clinical research services in Japan, South Korea, Taiwan and China. QPS and intellim will both own 50% of iQ Pharma Services, which they expect to launch in the fourth quarter of 2012.

Mr. Ukita, intellim's CEO, had the following to say about his company's relationship with QPS: "QPS is a first class CRO and, we believe, the ideal partner with which to build iQ Pharma Services. intellim will cover Japan and South Korea, and QPS will cover Taiwan, China and more. This alliance validates the strength of intellim's service portfolio and reputation, and the power of our business model to enable us to partner with other companies to promote our services. Because Japan is the second largest country for pharmaceutical companies in terms of new drug development and sales, and is interested in expanding its business to Asia and the other regions, we decided to base iQ Pharma Services in Japan. We believe iQ Pharma Services will quickly become essential to the pharmaceutical industry."

Mr. Ben Chien, QPS' CEO, summarized this venture by saying, "We are optimistic that iQ Pharma Services will become *the* CRO of choice for Phase II through Phase IV contract clinical research in the Pacific/Asia region. Indeed, this strategic alliance with intellim is the perfect addition to further our own evolution as a global CRO. We are already seeing increased regional demand and we believe this alliance with intellim will allow us to intensify our presence in the Pacific/Asia region."

###

### **About QPS**

*QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide, in the areas of CNS Pharmacology, Drug Metabolism and Pharmacokinetics, Toxicology, Bioanalysis, Translational Medicine, and Early Stage and Phase II-IV Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Preclinical Testing and Bioanalysis facilities at its Newark, DE headquarters; Groningen, the Netherlands; Graz, Austria; Taipei, Taiwan; and Hyderabad, India. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; Groningen, the Netherlands; and Hyderabad, India. Business development and Phase II-IV clinical research support offices are located in the USA, China, Taiwan, India, Netherlands, Austria, Czech Republic, Croatia, Slovenia, Serbia, Bosnia, Hungary, Spain, Germany and the United Kingdom. For more information, please visit [www.qps.com](http://www.qps.com)*

### **About intellim**

*intellim was founded in 2005. Its headquarters are in Osaka, Japan, with branch offices in Tokyo and Taipei, and a Korean subsidiary. The company provides Basic Research, Regulatory Consulting, DM/Stats, Monitoring and Audit services through both in- and outsourcing. Last year, the company began strengthening its global oncology development, bringing noted Medical Oncology expert Dr. Nagahiro Saijo on board as a special advisor. intellim is now the largest independent CRO in Japan. For more information, please visit [www.intellim.co.jp](http://www.intellim.co.jp)*